​San Diego, California/December 12, 2019 – Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.

Dr. Ming Wang, CEO, will be presenting Phanes Therapeutics, Inc. at Biotech Showcase as follows:

Date: Monday, January 13, 2020

Time: 10:30 AM (PST)

Room: Franciscan D (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

​Phanes Therapeutics is an emerging leader in innovative drug discovery in immuno-oncology. Founded in July 2016, Phanes is led by a team of industry veterans with extensive drug discovery and development experience in global pharma and biotech, including Pfizer, Amgen, and J&J.

​The company’s bispecific antibody platform is PACbody™, a proprietary approach for constructing bispecific antibodies without using protein engineering so that the antibody molecules maintain native structures with superb CMC characteristics. A second technology platform the company is developing is ATACC™, a proprietary technology for targeting solid tumors using immuno-oncology molecules with minimal risk of cytokine release syndrome (CRS). Its pipeline includes humanized single-chain variable fragments (scFv) against multiple tumor-specific antigens (TSAs) that are suitable for CAR-T applications.

​“We have signed two out-licensing deals in recent months, which is a strong validation of our scientific strength and innovative approach,” said Ming Wang, CEO of Phanes Therapeutics. “At Phanes, our mission is to become a major source of innovation in the biopharma industry. We are fully committed to delivering robust therapies to patients, but we can’t do it alone. We will continue to leverage partnerships with companies that have capabilities complementary to ours.”

​Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

​“We are delighted that Phanes Therapeutics will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery in immuno-oncology. Based in San Diego, California, the company’s management team members previously held senior managerial and R&D positions in leading global pharmaceutical and biotech companies with extensive experience in R&D, commercialization and business development. For more information, please visit